Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor.
Inhibition of HDAC leads to relaxed chromatin and increased transcription, causing accumulation of proteins and cell cycle arrest or apoptosis.
In preclinical development for multiple myeloma (MM), Farydak was able to overcome resistance to traditional drugs like dexamethasone and melphalan.
The drug also demonstrated the ability to enhance the efficacy of some established MM drugs, including Velcade (bortezomib; Takeda/Johnson & Johnson).
Early-stage development suggests that Farydak has very little effect as a monotherapy.
Key Topics Covered
- Drug Overview
- Product Profiles
- Farydak: Multiple myeloma
List of Figures
Figure 1: Farydak for multiple myeloma - SWOT analysis
Figure 2: The authors drug assessment summary of Farydak for multiple myeloma
Figure 3: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Farydak drug profile
Table 2: Farydak pivotal trial data in multiple myeloma
Table 3: Farydak early-phase trial data in multiple myeloma
Table 4: Farydak Phase II trial in multiple myeloma
Table 5: Farydak sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Patients treated with Farydak across the US, Japan, and five major EU markets, by country, 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/j69hvm